View ValuationInnate Pharma 将来の成長Future 基準チェック /26Innate Pharmaは、49.8%と46%でそれぞれ年率49.8%で利益と収益が成長すると予測される一方、EPSはgrowで111%年率。主要情報49.8%収益成長率111.02%EPS成長率Biotechs 収益成長23.2%収益成長率46.0%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日14 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 18Innate Pharma SA to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Innate Pharma SA announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California. The MATISSE study (NCT05742607) is a single arm Phase 2 clinical trial evaluating perioperative IPH5201, an anti-CD39 blocking antibody, in combination with perioperative durvalumab (anti-PD-L1) in addition to neoadjuvant platinum-based chemotherapy in previously untreated patients with resectable NSCLC. The trial is designed to assess whether dual inhibition of the CD39 and PD-L1 pathways, together with chemotherapy, can enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer. These results follow a pre-planned interim analysis on 40 patients. The combination of IPH5201 with durvalumab and chemotherapy demonstrated higher pathological complete response (pCR) rates compared with the benchmark set by durvalumab plus chemotherapy alone. Notably, pCR was 35.7% and 50% in patients with tumors expressing PD-L1 =1% and PD-L1 =50%, respectively. Based on these results, the study continues to recruit patients with tumors expressing PD-L1=1%. The presentation will be available in the publication section of Innate Pharma’s website. Abstract details: Dual CD39 and PD-L1 inhibition: Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC. Abstract Code: CT231. Session: CTPL04 – Advances in Immunotherapy. Session Date/Time: Tuesday, April 21, 2026, 10:45 – 11:00 AM PDT. IPH5201 is a first-in-class monoclonal antibody targeting CD39, a key immunosuppressive enzyme in the adenosine pathway. CD39 is expressed on tumor-infiltrating immune and stromal cells and contributes to immunosuppression by degrading extracellular adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is then further degraded into adenosine by CD73. By blocking CD39, IPH5201 promotes the accumulation of immunostimulatory ATP and reduces the production of immunosuppressive adenosine, thereby enhancing anti-tumor immune responses. IPH5201 is being co-developed in collaboration with AstraZeneca and is currently being evaluated in the Phase 2 MATISSE trial (NCT05742607), a multicenter study investigating perioperative treatment with IPH5201 in combination with durvalumab (anti-PD-L1) and platinum-based chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The MATISSE trial is designed to assess anti-tumor activity, including pathological complete response, and safety, with the goal of determining whether dual inhibition of the CD39 and PD-L1 pathways, in combination with chemotherapy, can enhance anti-tumor immunity and improve clinical outcomes in early-stage NSCLC.お知らせ • Apr 14Innate Pharma S.A., Annual General Meeting, May 21, 2026Innate Pharma S.A., Annual General Meeting, May 21, 2026. Location: 117 avenue de luminy, marseille FranceReported Earnings • Mar 27Full year 2025 earnings released: €0.55 loss per share (vs €0.61 loss in FY 2024)Full year 2025 results: €0.55 loss per share (improved from €0.61 loss in FY 2024). Revenue: €9.01m (down 55% from FY 2024). Net loss: €49.2m (flat on FY 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.Board Change • Mar 20High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 02High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Dec 11+ 1 more updateInnate Pharma S.A. to Report Fiscal Year 2025 Results on Mar 26, 2026Innate Pharma S.A. announced that they will report fiscal year 2025 results Pre-Market on Mar 26, 2026お知らせ • Nov 10Innate Pharma Announces FDA Clearance to Proceed with TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CCLInnate Pharma SA announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed. The planned confirmatory Phase 3 trial, TELLOMAK 3, is an open-label, randomized study designed to demonstrate the efficacy of lacutamab in patients with Sezary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. The trial will include two independent cohorts: one enrolling patients with Sezary syndrome post-mogamulizumab treatment randomized 1:1 to receive lacutamab or romidepsin, and one enrolling patients with Mycosis fungoides randomized 1:1 to receive Lacutamab or mogamulizumab. Data from the Phase 2 TELLOMAK trial in CTCL demonstrated durable activity, a favorable safety profile, and improvements in patients' quality of life. With this feedback from FDA, the Company is progressing towards the initiation of the confirmatory Phase 3 TELLOMAK 3 trial in H1 2026. FDA provided encouraging initial feedback on Innate Pharma's proposed regulatory pathway, which could potentially include Accelerated Approval for Sezary syndrome, once the Phase 3 trial is underway. Data from the Phase 2TELLOMAK trial in C TCL demonstrated durable activity, a favourable safety profile, and improvements in patient' quality of life. FDA provided encouraging initial feedback On Innate Pharma's proposed regulatory pathways, which could potentially include Acceleration Approval for Sezary Syndrome, once the Phase 3 trial are underway. Data from the Phase 3 TELLOMAK trial in cTCL demonstrated durable activity, an favorable safety profile, and improvement in patients' quality of life; With this feedback from FDA, PRIME designation from the EMA for SS, and Orphan Drug designation in both the US and EU for CTCL. More recently it has received Breakthrough Therapy Designation for SS. A Phase 3 in CTCL is under preparation.Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 17Innate Pharma S.A. Appoints Yannis Morel as Chief Scientific OfficerInnate Pharma S.A. announced that as Chief Operating Officer (COO), Yannis Morel will continue to be responsible for preclinical research and development, and will assume Chief Scientific Officer (CSO) responsibilities.業績と収益の成長予測XTRA:IDD - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202841-51-62-54312/31/202765-182735612/31/202631-29-19-11612/31/20259-49-53-53N/A9/30/202511-48-47-47N/A6/30/202513-46-41-41N/A3/31/202516-48-24-24N/A12/31/202420-49-7-7N/A9/30/202427-42-14-12N/A6/30/202434-34-20-18N/A3/31/202448-21-28-25N/A12/31/202362-8-35-33N/A9/30/202357-35-34-32N/A6/30/202352-63-33-32N/A3/31/202355-60-27-25N/A12/31/202258-58-20-19N/A9/30/202257-40-24-23N/A6/30/202257-22-28-26N/A3/31/202241-34-44-42N/A12/31/202125-45-60-58N/A6/30/202146-8-27-25N/A3/31/202158-4-45-38N/A12/31/202070-1-63-52N/A9/30/202067-54-78-67N/A6/30/202063-44-93-83N/A3/31/202075-33-62-24N/A12/31/2019858-3035N/A9/30/20191085N/A48N/A6/30/201913031N/A61N/A3/31/201911217N/A14N/A12/31/2018943N/A-33N/A9/30/201870-19N/A-46N/A6/30/201846-40N/A-59N/A3/31/201845-44N/A-53N/A12/31/201744-48N/A-48N/A9/30/201755-28N/A-43N/A6/30/201766-8N/A-38N/A3/31/2017663N/A-37N/A12/31/20166613N/A-37N/A9/30/2016535N/A-33N/A6/30/201641-2N/A-29N/A3/31/201633-4N/A86N/A12/31/201525-7N/A202N/A9/30/201517-13N/A200N/A6/30/20158-19N/A199N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: IDD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: IDD今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: IDD今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: IDDの収益 ( 46% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: IDDの収益 ( 46% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: IDDの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 19:55終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innate Pharma S.A. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Justin ZelinBTIGSuranjit MukherjeeBTIGYigal NochomovitzCitigroup Inc10 その他のアナリストを表示
お知らせ • Apr 18Innate Pharma SA to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Innate Pharma SA announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non-small cell lung cancer (NSCLC) will be presented in one of the Clinical Trials Plenary Sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026 in San Diego, California. The MATISSE study (NCT05742607) is a single arm Phase 2 clinical trial evaluating perioperative IPH5201, an anti-CD39 blocking antibody, in combination with perioperative durvalumab (anti-PD-L1) in addition to neoadjuvant platinum-based chemotherapy in previously untreated patients with resectable NSCLC. The trial is designed to assess whether dual inhibition of the CD39 and PD-L1 pathways, together with chemotherapy, can enhance anti-tumor immune responses and improve clinical outcomes in early-stage lung cancer. These results follow a pre-planned interim analysis on 40 patients. The combination of IPH5201 with durvalumab and chemotherapy demonstrated higher pathological complete response (pCR) rates compared with the benchmark set by durvalumab plus chemotherapy alone. Notably, pCR was 35.7% and 50% in patients with tumors expressing PD-L1 =1% and PD-L1 =50%, respectively. Based on these results, the study continues to recruit patients with tumors expressing PD-L1=1%. The presentation will be available in the publication section of Innate Pharma’s website. Abstract details: Dual CD39 and PD-L1 inhibition: Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in patients with resectable NSCLC. Abstract Code: CT231. Session: CTPL04 – Advances in Immunotherapy. Session Date/Time: Tuesday, April 21, 2026, 10:45 – 11:00 AM PDT. IPH5201 is a first-in-class monoclonal antibody targeting CD39, a key immunosuppressive enzyme in the adenosine pathway. CD39 is expressed on tumor-infiltrating immune and stromal cells and contributes to immunosuppression by degrading extracellular adenosine triphosphate (ATP) into adenosine monophosphate (AMP), which is then further degraded into adenosine by CD73. By blocking CD39, IPH5201 promotes the accumulation of immunostimulatory ATP and reduces the production of immunosuppressive adenosine, thereby enhancing anti-tumor immune responses. IPH5201 is being co-developed in collaboration with AstraZeneca and is currently being evaluated in the Phase 2 MATISSE trial (NCT05742607), a multicenter study investigating perioperative treatment with IPH5201 in combination with durvalumab (anti-PD-L1) and platinum-based chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The MATISSE trial is designed to assess anti-tumor activity, including pathological complete response, and safety, with the goal of determining whether dual inhibition of the CD39 and PD-L1 pathways, in combination with chemotherapy, can enhance anti-tumor immunity and improve clinical outcomes in early-stage NSCLC.
お知らせ • Apr 14Innate Pharma S.A., Annual General Meeting, May 21, 2026Innate Pharma S.A., Annual General Meeting, May 21, 2026. Location: 117 avenue de luminy, marseille France
Reported Earnings • Mar 27Full year 2025 earnings released: €0.55 loss per share (vs €0.61 loss in FY 2024)Full year 2025 results: €0.55 loss per share (improved from €0.61 loss in FY 2024). Revenue: €9.01m (down 55% from FY 2024). Net loss: €49.2m (flat on FY 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
Board Change • Mar 20High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 02High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 11+ 1 more updateInnate Pharma S.A. to Report Fiscal Year 2025 Results on Mar 26, 2026Innate Pharma S.A. announced that they will report fiscal year 2025 results Pre-Market on Mar 26, 2026
お知らせ • Nov 10Innate Pharma Announces FDA Clearance to Proceed with TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CCLInnate Pharma SA announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed. The planned confirmatory Phase 3 trial, TELLOMAK 3, is an open-label, randomized study designed to demonstrate the efficacy of lacutamab in patients with Sezary syndrome and Mycosis fungoides, who failed at least one prior line of systemic therapy. The trial will include two independent cohorts: one enrolling patients with Sezary syndrome post-mogamulizumab treatment randomized 1:1 to receive lacutamab or romidepsin, and one enrolling patients with Mycosis fungoides randomized 1:1 to receive Lacutamab or mogamulizumab. Data from the Phase 2 TELLOMAK trial in CTCL demonstrated durable activity, a favorable safety profile, and improvements in patients' quality of life. With this feedback from FDA, the Company is progressing towards the initiation of the confirmatory Phase 3 TELLOMAK 3 trial in H1 2026. FDA provided encouraging initial feedback on Innate Pharma's proposed regulatory pathway, which could potentially include Accelerated Approval for Sezary syndrome, once the Phase 3 trial is underway. Data from the Phase 2TELLOMAK trial in C TCL demonstrated durable activity, a favourable safety profile, and improvements in patient' quality of life. FDA provided encouraging initial feedback On Innate Pharma's proposed regulatory pathways, which could potentially include Acceleration Approval for Sezary Syndrome, once the Phase 3 trial are underway. Data from the Phase 3 TELLOMAK trial in cTCL demonstrated durable activity, an favorable safety profile, and improvement in patients' quality of life; With this feedback from FDA, PRIME designation from the EMA for SS, and Orphan Drug designation in both the US and EU for CTCL. More recently it has received Breakthrough Therapy Designation for SS. A Phase 3 in CTCL is under preparation.
Board Change • Oct 28High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Strategic Advisory Board Member Aurelien Marabelle is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 17Innate Pharma S.A. Appoints Yannis Morel as Chief Scientific OfficerInnate Pharma S.A. announced that as Chief Operating Officer (COO), Yannis Morel will continue to be responsible for preclinical research and development, and will assume Chief Scientific Officer (CSO) responsibilities.